Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SCLX |
---|---|---|
09:32 ET | 7914 | 0.98 |
09:34 ET | 4407 | 0.9336 |
09:36 ET | 6158 | 0.9599 |
09:38 ET | 1000 | 0.95 |
09:39 ET | 16400 | 0.93 |
09:41 ET | 300 | 0.93 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Scilex Holding Co | 220.6M | -0.7x | --- |
Eton Pharmaceuticals Inc | 133.1M | -22.0x | --- |
Elite Pharmaceuticals Inc | 384.7M | 20.4x | --- |
Cipla Ltd | 16.0B | 0.0x | --- |
Cumberland Pharmaceuticals Inc | 18.2M | -1.7x | --- |
Calliditas Therapeutics AB | 1.2B | 0.0x | --- |
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $220.6M |
---|---|
Revenue (TTM) | $50.8M |
Shares Outstanding | 191.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.17 |
EPS | $-1.40 |
Book Value | $-1.73 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 4.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -181.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.